A multidisciplinary forum: How can we improve management of hormone-sensitive prostate cancer?
Industry session by FERRING PHARMACEUTICALS
-
Location:Room Vienna, North Hall (Level 1)
-
Chair:
-
Aims and objectives of this session • A multidisciplinary panel of clinicians will share best practice around the current place of androgen deprivation therapy (ADT) in the treatment of hormone-sensitive prostate cancer across the different stages of the disease
– To include treatment adjuvant to surgery and radiation
– In combination with chemotherapy
• Highlight the differences in mechanism of action and compare efficacy and safety profiles of different ADT agents
• Discuss future directions in hormonal treatment of prostate cancer